Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).

Abstract: Provided are new and improved methods for detecting circulating tumor cells and tumor cell DNA in patient blood or other biofluid samples. Particular aspects comprise three steps: DNA extraction from patient samples, DNA digestion with multiple selected methylation-sensitive enzymes, and target amplification by a conventional or a real-time PCR with specific probe and/or primers. Also provided are a total of 40 tumor-specific DNA methylation loci as biomarkers having substantial utility and specificity in major types of human malignancies including hematopoietic and solid tumors.

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.

Abstract: The invention provides a novel class of compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).

Abstract: This invention relates to 2-aza-bicyclo[2.2.1]heptane compounds (and salts thereof), the process for making such a compound and pharmaceutical compositions comprising such a compound. The invention also relates to the use of the compounds for modulating the glycine transporter 1 (GlyT1) and for the treatment of psychosis, cognitive disorders, bipolar disorders, depression disorders, anxiety disorders, post-traumatic stress disorders and pain.

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).

Abstract: The invention provides a novel class of compounds of the Formula I: in which the symbols have the meanings given in the description and claims, to pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of FGFR3 kinase.

Abstract: Method for manufacturing a protein filling agent for leather utilizing animal hairs. The method includes pre-treating the animal hairs to obtain pre-treated animal hairs, wherein the pre-treating comprises soaking the animal hairs in an inorganic acid solution and a reducing agent solution. Next, the pre-treated hairs are hydrolyzed in an alkaline compound to obtain a viscous liquid and then, neutralized and dried to obtain the protein filling agent for leather.

Abstract: A near-eye display related apparatus and device is disclosed. The apparatus includes a housing configured to receive an optical engine, and a light guiding plate attached to the housing and configured to receive light representing an image from the optical engine, the light guiding plate includes a first diffractive grating adapted to incouple the light into the light guiding plate, and a second diffractive grating adapted to outcouple the light from the light guiding plate such that the light is received by an eye of a user wearing the apparatus. The light guiding plate has a contact surface portion configured to optically couple the light guiding plate to a transparent plate, The contact surface portion being adapted to be in physical contact with the transparent plate.

Abstract: A method for integrating an operating system (OS) into a basic input output system (BIOS) chip and to boot a computer using programs stored in the BIOS. A bootable image file of the OS is integrated with a virtual disk program and other BIOS instructions and stored into the BIOS chip. When the computer is powered up and upon the condition that an OS in a hard disk of a computer system is damaged, the OS in the BIOS chip is executed.

Abstract: A method for integrating an operating system (OS) into a basic input output system (BIOS) chip and to boot a computer system using an image file stored in a server. A bootable image file of the OS is integrated with a virtual disk program and other BIOS instructions and stored into the BIOS chip. When the computer system is powered up, the OS stored in the BIOS can be booted to allow the another OS stored in the server to be downloaded into the harddisk and executed. The BIOS OS can also allow an OS stored on the local drive to be executed.

Abstract: A stylus retaining mechanism for portable electronic device includes a main body, a latching portion, and an elastic member. The main body defines an opening and a receiving chamber communicating with the opening. The latching portion is positioned at one side of the receiving chamber spaced from the opening. The elastic member is fixed in the receiving chamber adjacent to the opening. The stylus is received in the receiving chamber. The elastic member prevents the stylus from separating from the main body when the stylus is disengaged from the latching portion.

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bcr-Abl(T315I), ALK, BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-1R, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFR?, Ros, SAPK2?, SGK, SIK, Syk, Tie2 and TrkB kinases.

Abstract: The present invention provides a detecting method of detecting malignant cells in a patient's specimen or a biological sample. Specifically, the inventive method includes the steps of extracting a genomic DNA, digesting said genomic DNA with one or multiple methylation sensitive restriction enzymes, and amplifying by PCR with one or multiple selected primers. The PCR can be performed in a conventional or a real-time platform. The inventive method can detect leukemia cells in 90% ALL patients at a sensitivity of up to 10?6. The inventive method also provides broad clinical applications in cancer (including hematopoietic and solid tumors) screening and risk assessment, early detection and diagnosis confirmation, and therapeutic monitoring, minimal residual disease detection and prognostic prediction.

Abstract: The invention provides a novel class of compounds of the Formula I: in which the symbols have the meanings given in the description and claims, to pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of FGFR3 kinase.

Abstract: The invention provides a novel class of compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).

Abstract: A near-eye display related apparatus and device is disclosed. The apparatus includes a housing configured to receive an optical engine, and a light guiding plate attached to the housing and configured to receive light representing an image from the optical engine, the light guiding plate includes a first diffractive grating adapted to incouple the light into the light guiding plate, and a second diffractive grating adapted to outcouple the light from the light guiding plate such that the light is received by an eye of a user wearing the apparatus. The light guiding plate has a contact surface portion configured to optically couple the light guiding plate to a transparent plate, The contact surface portion being adapted to be in physical contact with the transparent plate.

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, ??K, T??2, ???, ?NK2?2, MKK4, c-RAF, MKK6, SAPK2? and SAPK2? kinases.

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bcr-Abl(T315I), ALK, BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-1R, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFR?, Ros, SAPK2?, SGK, SIK, Syk, Tie2 and TrkB kinases.

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.